SCUBE3 and breast carcinoma: We further examined the expression of SCUBE3 in breast cancer based on patient’s age (21–40, 41–60, 61–80, and 81–100), node metastasis status (N0, N1, N2, and N3), individual cancer stage (stage 1, stage 2, stage 3, and stage 4), and subclasses (luminal, HER2 + , and triple negative) using the UALCAN database.